CLDX Q2 2024 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+832.1% YoY

Gross Profit

$2M68.1% margin

Operating Income

-$46M-1854.2% margin

Net Income

-$36M-1434.8% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

+1501.3%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$30M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$846M

Total Liabilities

$32M

Stockholders' Equity

$814M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$268,000	+832.1%
Gross Profit	$2M	-$26M	+106.5%
Operating Income	-$46M	-$33M	-39.5%
Net Income	-$36M	-$31M	-17.5%

Revenue Segments

Grant

$2M100%

Service

$2,0000%